Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 10/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15267481 | 1.00 | TLR2 (0.44) | TLR2PLA2G10PLA2G2APLA2G1BPLA2G5 | |
| SCHEMBL25869482 | 1.00 | TLR2 (0.44) | TLR2PLA2G10PLA2G2APLA2G1BPLA2G5 | |
| SCHEMBL10581723 | 0.84 | MEN1 (0.41) | TLR2BCHEACHE | |
| Hydrochloric Acid SCHEMBL10582528 | 0.83 | TSHR (0.42) | TLR2 | |
| SCHEMBL3242956 | 0.81 | TLR2 (0.45) | TLR2PLA2G10PLA2G2APLA2G1BPLA2G5 | |
| SCHEMBL3237159 | 0.81 | TLR2 (0.45) | TLR2PLA2G10PLA2G2APLA2G1BPLA2G5 | |
| SCHEMBL3239027 | 0.81 | TLR2 (0.45) | TLR2PLA2G10PLA2G2APLA2G1BPLA2G5 | |
| SCHEMBL3239477 | 0.81 | TLR2 (0.45) | TLR2PLA2G10PLA2G2APLA2G1BPLA2G5 | |
| SCHEMBL3244717 | 0.81 | TLR2 (0.45) | TLR2PLA2G10PLA2G2APLA2G1BPLA2G5 | |
| SCHEMBL2839872 | 0.80 | ALDH1A1 (0.45) | TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | TLR2 1063/4885PLA2G10 710/4885PLA2G2A 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.